BACKGROUND: A transition from one health care setting to another increases the risk of medication errors. Several strategies have been applied to improve care transitions and reduce adverse clinical outcomes. Pharmacist intervention during and after hospitalization has been frequently studied and show a variable effect on these outcomes.
transition from one health care setting to another increases the risk of medication errors. Medication errors have been particularly attributed to poor communication or loss of important information. 1 These errors can result in clinically relevant outcomes such as adverse drug events (ADEs), increased duration of hospital stay, early readmissions after discharge, and use of other health care resources. 2 Although ADEs generally are the most invasive type of drug-related problems (DRPs), other DRPs may also result in patient harm, which then results in unplanned hospital readmissions. 3 Numerous strategies have been applied to reduce the number of ADEs and (drug-related) readmissions by involving various health care professionals such as nurses and pharmacists. [4] [5] [6] [7] Because of the likely link between DRPs and adverse
• Transitions between health care settings increase the risk of medication errors, which can result in adverse drug events, prolonged hospital stay, early readmissions, and use of other health care resources.
• Pharmacist intervention during and after hospitalization have been frequently studied, albeit with varied effects on clinical outcomes.
• Several systematic reviews have been performed studying care transition programs, although none have done so by separating pharmacist intervention components from continuity of care programs.
What is already known about this subject
• Our model systematically categorized components of pharmacist intervention in care transition programs. Study heterogeneity enabled a best evidence synthesis to elucidate effective components.
• This review revealed that multifaceted programs should combine medication reconciliation with active patient counseling and a clinical medication review. Care continuity can be secured by integrating pharmacists across settings and providing them with patients' clinical background.
• Collaborating with other health care professionals is crucial to increase the effectiveness of pharmacist intervention.
clinical outcomes, pharmacists may be the preferred health care provider to intervene and reduce the risks involved in care transitions, a view endorsed by 2 Institute of Medicine reports. 8, 9 Pharmacist intervention during and after hospitalization has been studied, albeit with varying effects on clinical outcomes. Some studies have shown significant reduction in drug-related readmissions, whereas others have shown improved surrogate outcomes (e.g., medication appropriateness or knowledge) but lacked significant impact on readmissions or had no effect at all. [10] [11] [12] [13] Other studies have revealed a significant reduction in readmission rates but did not use a randomized study design. 14, 15 Several systematic reviews have studied care transition programs. 2, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] However, these reviews focused either on a specific intervention component (e.g., hospital-based medication reconciliation); an isolated health care setting (e.g., an inpatient care setting); a specific high-risk population (e.g., heart failure patients); included only 1 outcome (e.g., readmissions); or did not specifically target pharmacist intervention. Finally, most reviews lacked an extensive description of the intervention components deployed in the included studies.
The purpose of this systematic review was to focus specifically on unraveling the components of pharmacist intervention from continuity of care programs that improved clinical outcomes.
■■ Methods Search Strategy
This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines (Appendix A, available in online article). 30 Three electronic databases were searched (MEDLINE, EMBASE, and International Pharmaceutical Abstracts [IPA] ) from inception to November 2014. Randomized controlled trials (RCTs) investigating interventions with regard to adult hospitalization and discharge with a proactive role for a pharmacist of any type (e.g., hospital, community, clinical) were identified (Appendix B, available in online article). The search strategy was designed in MEDLINE using the following medical subject headings and text words: patient education, counseling, medication therapy management, medication errors/prevention and control, medication reconciliation, continuity of patient care, patient care planning, aftercare, house calls, and drug utilization review. Synonymous terms combined with words for hospital admission and pharmacist profession were also used (see Appendix C for detailed search terms, available in online article). Only studies in English were included. The search strategy was further refined and validated by indexing known relevant articles. For EMBASE and IPA, search terms were adapted according to the capabilities of these particular databases. Reference lists of all included trials, previous systematic reviews, and the citation indexing service Web of Science were checked manually for additional relevant publications.
creating a pharmacist intervention model (Table 1 ) covering all components. 3. The 15 intervention components included in the pharmacist intervention model were structured by applying 3 types of clustering (Table 1) : a. Target: patient-aimed or HCP-aimed interventions. b. Nature: pharmacist professional care or administrative interventions. Professional care interventions included all services using pharmacists' skills and knowledge for an active role in patient health care. Administrative interventions comprised providing and handling of documents, for example. c. Stage: intervention performed at admission, during admission, at discharge, postdischarge, or stage-independent. 4. All outcomes were extracted, and-if not supplied by the respective study authors-effectiveness rates were calculated. Studies were categorized as "effective" in cases where at least 1 of the predefined outcomes was statistically significant (inclusion criteria, Appendix B). In case of a mixed effect (e.g., a significant increase in ADEs and a significant decrease in emergency department visits), the following priority of clinical relevance was applied: (a) mortality, (b) readmissions, (c) emergency department visits, and (d) ADEs, with the latter being the least relevant. Statistical significance was set at P < 0.05. 5. Average numbers of intervention components according to the clusters previously mentioned were compared between effective and ineffective studies. Data were checked for normality, and either an independent t-test or Mann-Whitney U test was performed to detect significant differences (P < 0.05).
Finally, a best evidence synthesis was conducted according to the framework proposed by Treadwell et al. (2012) . 34 Since our review included only RCTs, a stringent threshold in methodological quality was used to define the "best evidence set" by including studies with 5 or more bias-free domains. To attribute various levels of evidence to the effectiveness of the pharmacist intervention components, all reported study parameters ([combinations of] interventions, intervention stages, coinvolved HCPs, pharmacist type, setting characteristics) were taken into account. Evidence levels were based on van Tulder et al. (2003) 35 and are as follows: (a) Strong-consistent findings among multiple high quality RCTs; (b) Moderate-findings in 1 high quality RCT; and (c) Conflicting-inconsistent findings among multiple high quality RCTs. Since only RCTs were included, the levels Limited evidence and No evidence were not applicable.
■■ Results

Study Selection
The searches identified 3,084 records, which resulted in 2,619 nonduplicate items. Thirty papers met the inclusion criteria and were included in this systematic review (Figure 1 ).
6,10-13, The observed similarity between the 2 author/reviewers for full-text screening was 94% (inter-rater agreement κ = 0.87, Appendix E, available in online article), and all disagreements were resolved through discussion. Reasons for exclusion at this stage are given in Appendix F (available in online article).
Study Characteristics
The 30 included studies covered all Western continents: North America (n = 15), Europe (n = 10), and Australia (n = 5). Just over half of the studies (n = 17) were conducted in an academic, teaching, or tertiary referral hospital (Table 2) . Eleven studies implemented a hospital-wide intervention program, whereas others focused on patients in specific wards (mainly internal or general medicine, n = 11). The number of included patients varied considerably among the studies (range = 34-936). Subjects in both arms of these studies were generally well matched. Eighteen studies included patients with predefined health conditions or other high-risk factors. These were mainly chronic heart failure (n = 8) or acute hospital admission (n = 5; Table 2 ).
Quality Assessment of Individual Studies
Of the total 180 domains, 19% (n = 34) were scored differently by the 2 reviewers and resolved through discussion. Eight studies scored low risk for bias in all 6 domains (Appendix G, available in online article). 13, [39] [40] [41] 48, 54, 55, 59 Of the items in the selection bias, detection bias, attrition bias, and reporting bias domains, 11% could not be assessed due to insufficient data in the original studies. Five studies were considered at high risk for other bias; all had contamination bias because the same pharmacist took care of the intervention and control groups. 10, 11, 45, 56, 58 Finally, there was an unclear risk of other bias with an unclear effect on study outcomes in 10 studies: possible contamination bias, 12,44,49,50 possible compliance bias, 36, 42, 57 possible recall bias of participants, 51,60 and baseline differences with lack of power for adequate conclusions.
37
Results of Individual Studies: Pharmacist Interventions and Outcome Measurements
The overall number of intervention components for a specific outcome is presented in Appendix H (available in online article). This cross-tab illustrates, together with the heterogeneity in studied populations and coinvolved HCPs, the dissimilarity of included studies (Table 2 and, for background data, Appendix I, available in online article).
Patient-centered follow-up is the most deployed intervention (n = 19), followed by HCP-centered follow-up (n = 14; Appendix J, available in online article). Other frequently used interventions were medication review during admission (n = 13), patient counseling at discharge (n = 13), and admission reconciliation (n = 11; Appendix J). Most studies measured readmissions (n = 24), followed by mortality (n = 15), emergency department visits (n = 10), and ADEs (n = 4; Table 2 ). Only 2 studies reported a composite outcome measurement (composite readmission/emergency department visits and composite readmission/emergency department visits/ mortality, respectively) impeding analysis of the individual outcomes.
12,42
Results of Individual Studies: Effectiveness of Interventions Study effects are shown in Table 2 . All 30 studies showed a consistent effect on the outcomes included in this review. One study reported a significant increase in hospital readmissions at 6 months postdischarge. 39 The average number of different pharmacist intervention components deployed in effective versus ineffective studies was approximately the same, 4 • Postdischarge follow-up classification was based on intervention target.
• The subdivision in house calls (H), clinic visits (C), and telephone calls (T) is indicated in the results.
• Patient-centered follow-up comprises adherence counseling, for example.
Pt
P PD 11 HCP-centered follow-up
• See intervention 10.
• HCP-centered follow-up consists of reporting drug-related problems to general practitioner, for example. average-covered stages (1.9 vs. 2.1) and stage-independent interventions (0.6 vs. 0.6) were equally distributed, resulting in seemingly corresponding study characteristics regarding the deployed pharmacist interventions. All data were nonnormally distributed, and none of these differences were statistically significant (P > 0.05).
HCP
Best Evidence Synthesis
The cutoff point of ≥ 5 bias-free domains yielded 15 studies, 9 effective and 6 ineffective, for the best evidence synthesis (Table 3) . 10,13,39-41,43,45,48,50-55,59 Levels of evidence were attributed to individual intervention components on improving the selected clinical outcomes.
Five studies, 3 effective and 2 ineffective, investigated the effect of isolated postdischarge intervention components indicating conflicting evidence. [39] [40] [41] 54, 55 The studies' characteristics varied, since all 3 effective studies incorporated active nurse involvement either during the follow-up intervention or at hospital discharge. Furthermore, effective studies implemented individual patient tailoring, whereas ineffective studies had 1 or more additional follow-up contact moments.
Ten studies covered 1 or more hospital stages or combined in-hospital with postdischarge intervention components. By analyzing the individual components of these multifaceted interventions, different best evidence synthesis levels could be assigned. There is strong evidence for active pharmacist involvement during admission by performing a level 3 medication review. This level also requires active physician involvement (Table 3) . Five effective studies incorporated this intervention component, compared with none of the ineffective studies.
10,50-53 In 2 out of these 5 effective studies, the pharmacist was also part of the multidisciplinary medical team.
10,50 All other intervention components revealed conflicting evidence. Five studies (3 effective and 2 ineffective) incorporated medication reconciliation on admission.
10,13,52,53,59 Two of the effective studies combined reconciliation with patient counseling on admission.
10,53 Five studies (3 effective and 2 ineffective) covered 3 or more stages from hospital admission to postdischarge follow-up. 10, 13, 51, 53, 59 Finally, 7 studies (3 effective and 4 ineffective) combined a postdischarge intervention with 1 or more in-hospital intervention. 10, 13, 43, 45, 48, 51, 59 The postdischarge intervention components varied mainly in thoroughness.
■■ Discussion
All included studies varied regarding the type and moment of intervention, studied population, involvement of other health care providers, and selected outcomes. This variability is reflected in the clinical outcomes of these studies. Although this heterogeneity resulted in inconclusiveness of our predefined clustering to elucidate the most effective intervention components, the heterogeneity also enabled a best evidence synthesis. This synthesis suggests that for an isolated postdischarge program, pharmacists are most likely to contribute to improved patient outcomes by closely collaborating with nurses. Moreover, in multifaceted programs, pharmacists have additional value by performing a clinical medication review in addition to patient-involved medication reconciliation followed up by a thorough postdischarge intervention. Finally, the best evidence synthesis suggests that these pharmacist 
Characteristics of Studies Included in Systematic Review (continued)
pharmacist, respectively. The third study brought nurses into action to coordinate the discharge plan with the hospital team and educate and prepare patients for discharge. 41 These results indicate the need for a multidisciplinary intervention, which is in agreement with earlier findings. 19 Next, tailoring the intervention, for instance by assessing patient knowledge of the prescribed medications and compliance, was utilized in all effective studies (in Jack et al., 2009, 41 nurses used tailored intervention during hospital discharge). This practice is in contrast with the ineffective studies, which had the more general approach of offering medication boxes to every patient involved, for example. 39, 40, 61 The need for tailoring intervention to patient needs is further illustrated by the ineffective studies, interventions are especially effective when performed in close collaboration with physicians.
The conflicting evidence regarding studies investigating an isolated postdischarge intervention possibly originates from the variances in study conditions. 39-41,54,55 As mentioned earlier, all 3 effective studies involved a pharmacist's follow-up in close collaboration with a nurse. In 2 studies, this involvement was realized by performing a home-based follow-up as a pharmacist-nurse team. 54, 55 In those cases, the nurse focused on detecting any clinical deterioration, whereas the pharmacist focused mainly on adherence counseling and adequate monitoring by caregivers. If necessary, both HCPs deployed a subsequent referral to either the general practitioner or community Three studies covered all stages from hospital admission to postdischarge followup. 10, 13, 59 Analysis of the in-hospital intervention components of Gillespie et al. (2009) 10 -one of the effective studies-revealed that pharmacists participated in ward rounds and as members of the medical team, in contrast to the ineffective studies.
13,59
During those ward rounds, pharmacists discussed the identified drug-related problems with the responsible physicians, which possibly improved implementation of the pharmacists' recommendations. Moreover, at hospital discharge, Gillespie et al. provided the patients' general practitioner with an extensive pharmacist discharge letter containing all in-hospital changes (with rationale), monitoring needs, expected therapeutic goals, and outstanding drug-related problems (with suggested actions).
10 Farris et al. (2014) deployed a similar intervention, but the ineffectiveness could be attributed to the use of a research pharmacist (as mentioned earlier) or lack of contrast between intervention and control groups. 59 So, to be successful in reducing clinical outcomes such as hospital readmission, a more extensive pharmacist presence during all stages might be beneficial. However, it is crucial that the pharmacist acts in close collaboration with either the hospital-based team or the primary care provider.
In-depth analysis of the design of the postdischarge interventions in the 7 multifaceted programs that combined a postdischarge intervention with 1 or more in-hospital interventions showed great variance.
10,13,43,45,48,51, 59 The effective studies-Gillespie et al. 10 and LÓpez Cabezas et al. (2006) 45 -used a follow-up telephone call to reinforced in-hospital provided interventions, and Schnipper et al. (2006) 51 combined telephone reinforcement with active feedback to primary care providers. Regarding the ineffective studies, Nazareth et al. (2001) 48 supplied the community pharmacists with only the patients' discharge medication regimens and focused on patient compliance and knowledge during the pharmacist house call. Although the intervention was fairly thorough, the community pharmacists were not supplied with the patients' previous clinical histories. Another ineffective study, Kripalani et al. (2012) , 13 incorporated a pharmacist follow-up telephone call "as needed," risking the possibility of missing relevant interventions, and the results of Farris et al. 59 might be flawed by a less rigorous implementation of medication-related recommendations postdischarge. Finally, Lipton and Bird (1994) 43 focused mainly on compliance by reducing regimen complexity during a telephone call. So, although not conclusive, evidence tends towards performing a comprehensive postdischarge follow-up based on previous in-hospital interventions by a pharmacist who is equipped with the patient's previous medical history. which deployed additional follow-up visits to reinforce original advice. Although in itself this might be a valuable intervention component, it should possibly be tailored to specific patient needs or population to optimize its efficacy. Finally, effective studies deployed a pharmacist from the involved hospital, whereas ineffective studies deployed an external research pharmacist who was neither familiar with the patients' home situations nor the previous hospital stays. Hence, as hospital discharge is well known to be confusing and distressing, 62, 63 this might increase the risk of discontinuity of care.
Regarding the multifaceted programs, several implications for daily practice can be extracted. Although individual effects of multifaceted interventions are difficult to determine, the best evidence synthesis imposed strong evidence for the effectiveness of medication review during hospital admission. Six multifaceted intervention programs incorporated this intervention component, but the level of assessing medication appropriateness varies between studies.
10,13,50-53,64 The 5 effective studies performed a rigorous clinical medication review (level 3) as compared with 1 ineffective study that performed an adherence support review (level 2). A level 3 review aimed at optimization of pharmacotherapy with access to clinical notes enables pharmacists to address the patients' use of medications in the context of their clinical conditions. Furthermore, a level 3 medication review during hospital admission requires a close collaboration with the responsible physician. Since only the effective studies incorporated this rigorous review, the beneficial effect might also be attributed to the multidisciplinary collaboration between pharmacists and physicians.
Several multifaceted intervention programs deployed medication reconciliation on admission but differed in setting by active patient involvement.
10,13,52,53,59 A recent report by the Agency for Healthcare Research and Quality (AHRQ) evaluated the role of pharmacists during care transition programs.
65
This report recommends medication reconciliation during care transition to minimize risks. However, to obtain a best possible medication history, medication reconciliation needs to be supplemented with a structured patient interview.
16 All 3 effective studies included this intervention, either by the pharmacist or by the attending physician, in contrast to the 2 ineffective studies that did not include the interview. 13, 59 This indicates that a structured patient interview needs to be part of admission reconciliation, but it does not necessarily need to be conducted by a pharmacist. Kwan et al. (2013) suggested that performing medication reconciliation alone is not sufficient to reduce postdischarge clinical outcomes (e.g., hospital readmission), since it needs to be combined with other interventions aimed at care transition improvement. 16 By incorporating an extensive combination of pharmacist interventions in hospital and primary health care
Limitations
This review has several strengths. First, the comprehensive search strategy utilized an automated database search of 3 pharmacy-relevant databases with manual reference tracking, which resulted in a complete overview of published studies in this field. Next, all articles were screened and extracted independently by 2 reviewers, ensuring that a solid selection of relevant studies and study characteristics were identified. Finally, because of a detailed data extraction process, it was possible to separate the various pharmacist intervention components.
First, an important limitation of this review is the risk of underreporting the deployed intervention components because of a possible lack of detailed descriptions in the original articles. Since only data from the original articles were extracted for the pharmacist intervention model, important components may have been missed. Second, although a comprehensive literature search was performed, publication bias is an important potential source of bias in systematic reviews.
31 Therefore, unpublished research was not included in our analysis. Third, the selected clinical outcomes for this review were not always the primary outcomes of the included studies, which might result in an included trial being underpowered. Although most included studies were effective on surrogate endpoints (e.g., knowledge or adherence), by excluding these data, only clinically relevant outcomes were investigated implying strong evidence. Finally, we included only articles published in English and may therefore have missed some relevant literature.
■■ Conclusions
Pharmacists can successfully perform interventions across different health care settings.
5,66 Although there is a need for well-designed and well-reported RCTs, this systematic review indicates several pharmacist intervention components that could reduce the risks involved during care transitions. When performing an isolated postdischarge intervention, evidence tends towards collaborating with nurses and tailoring interventions to individual patient needs. In multifaceted intervention programs, performing medication reconciliation alone is possibly insufficient in reducing postdischarge clinical outcomes and should be combined with active patient counseling and a clinical medication review during admission. Furthermore, close collaboration between pharmacists and physicians during all stages of hospitalization is beneficial. Finally, it is important to secure continuity of care by integrating an outreaching hospital pharmacist or a community pharmacist in these multifaceted programs across the health care settings. Ultimately, the pharmacist involved in the intervention needs to be provided with the patient's clinical background and previous hospital experience.
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Identifying the Optimal Role for Pharmacists in Care Transitions: A Systematic Review
Inclusion Criteria Study design
• (quasi) (cluster) Randomized controlled trial published in English Population
• Adult participants admitted to a hospital and discharged home Setting
• Intervention conducted in hospital and/or community pharmacy and/or patients' home Intervention
• The intervention involved a pharmacist, pregraduate pharmacist, or pharmacy technician • The pharmacist had a proactive role, meaning for all interventions, patients received an active pharmacist intervention (e.g., excluding reactively responding to physician questions during ward rounds) • Interventions were performed before, during, or up to 30 days after hospitalization. The postdischarge time limit was chosen to ensure connection to transitional care • The intervention was designed to improve transitional care and aimed at medication-related issues Comparison
• The intervention was compared with a control group that received usual care Clinical outcomes
• At least 1 of the following outcomes was measured: mortality, readmissions, emergency department visits, and adverse drug events
Exclusion Criteria
Participant
• Intervention conducted solely on pediatric patients or psychiatric patients due to their specific population characteristics Setting
• Interventions in a palliative care setting or in an intensive care ward due to their specific setting characteristics Intervention
• Interventions solely targeted at specific drugs (e.g., improving adherence of statins)
• Interventions not aimed at transitional care (e.g., interventions in outpatient clinics without transmission of relevant information from earlier health care provider encounters in the hospital or interventions on heart failure guideline adherence) PICO = participants, interventions, comparisons, and outcomes.
APPEnDIx B Inclusion and Exclusion Criteria According to PICO for Systematic Review
APPEnDIx C Search Strategy International Pharmaceutical Abstracts #1= TI ( "patient admission" OR "admission" OR "hospital admission" OR "hospitalization" OR "patient discharge" OR "discharge" OR "discharged" OR "post discharge" OR "postdischarge" OR "hospitals" OR "hospital setting" ) OR AB ( "patient admission" OR "admission" OR "hospital admission" OR "hospitalization" OR "patient discharge" OR "discharge" OR "discharged" OR "post discharge" OR "postdischarge" OR "hospitals" OR "hospital setting" ) #2= TI ( "patient education" OR "counseling" OR "counselling" OR "medication counseling" OR "knowledge" OR "drug knowledge" OR "medicines knowledge" OR "medication knowledge" OR "education" OR "medication understanding" OR "Medication Therapy Management" OR "integrated medicines management" OR "medicine* management" OR "drug* management" OR "Medication Errors" OR "medication reconciliation" OR "medication reconciliation" OR "medical history taking" OR "medication history" OR "medicines histories" OR "continuity of patient care" OR "Patient Care Planning" OR "discharge planning" OR "discharge service" OR "discharge booklet" OR "follow-up" OR "follow up" OR transition* OR "seamless" OR "care bundle" OR "care coordination" OR "aftercare" OR "continuity" OR "outreach" OR "co-ordination" OR "coordination" OR "house calls" OR "home visit*" OR "house visit*" OR "pharmacy visit" OR "pharmacist visit" OR "home based intervention" OR "telephone call*" OR "telephone" OR "phone call*" OR "phone" OR "medication review" OR "drug utilization review" OR "treatment review" OR "medication review" OR "medicines review" OR "drug review" OR "reviewing medication" OR "monitoring pharmacotherapy" OR "optimizing drug regimens" OR "pharmaceutical care" ) OR AB ( "patient education" OR "counseling" OR "counselling" OR "medication counseling" OR "knowledge" OR "drug knowledge" OR "medicines knowledge" OR "medication knowledge" OR "education" OR "medication understanding" OR "Medication Therapy Management" OR "integrated medicines management" OR "medicine* management" OR "drug* management" OR "Medication Errors" OR "medication reconciliation" OR "medication reconciliation" OR "medical history taking" OR "medication history" OR "medicines histories" OR "continuity of patient care" OR "Patient Care Planning" OR "discharge planning" OR "discharge service" OR "discharge booklet" OR "follow-up" OR "follow up" OR transition* OR "seamless" OR "care bundle" OR "care coordination" OR "aftercare" OR "continuity" OR "outreach" OR "co-ordination" OR "coordination" OR "house calls" OR "home visit*" OR "house visit*" OR "pharmacy visit" OR "pharmacist visit" OR "home based intervention" OR "telephone call*" OR "telephone" OR "phone call*" OR "phone" OR "medication review" OR "drug utilization review" OR "treatment review" OR "medication review" OR "medicines review" OR "drug review" OR "reviewing medication" OR "monitoring pharmacotherapy" OR "optimizing drug regimens" OR "pharmaceutical care" ) #3= TI ( "community pharmacy services" OR "Hospital Pharmacy Service" OR "pharmaceutical preparations" OR "drug prescriptions" OR "pharmacist*" OR "pharmacy" OR "pharmaceutical" OR "Pharmacists' Aides" OR "pharmacy technician" OR "pharmacy practitioners" OR "pharmacy service" OR "medication" OR "medication liaison services" ) OR AB ( "community pharmacy services" OR "Hospital Pharmacy Service" OR "pharmaceutical preparations" OR "drug prescriptions" OR "pharmacist*" OR "pharmacy" OR "pharmaceutical" OR "Pharmacists' Aides" OR "pharmacy technician" OR "pharmacy practitioners" OR "pharmacy service" OR "medication" OR "medication liaison services" ) #4= TI ( "randomized controlled trial" OR (randomized AND controlled AND trial) OR (randomised AND controlled AND trial) OR random* ) OR AB ( "randomized controlled trial" OR (randomized AND controlled AND trial) OR (randomised AND controlled AND trial) OR random* ) #5= #1 AND #2 AND #3 AND #4 To calculate Pr(e) (the probability of random agreement):
• Ensing said "Y" to 34 articles and "N" to 92 articles: Thus "Y" is 0.37 of the time.
• Stuijt said "Y" to 30 articles and "N" to 96 articles. Thus "Y" is 0.31 of the time.
• The probability that both say "Y" is 0.37 × 0.31 = 0.11.
• The probability that both say "N" is (1-0.37) × (1-0.31) = 0.43.
• Thus the overall probability of random agreement is Pr(e) = 0.11 + 0.43 = 0.54.
Resulting in: 
